Objectives This study sought to assess the feasibility and safety of a recently described technique of mechanical recanalization with the help of a stent-like device.
Intravenous (IV) tissue-type plasminogen activator (tPA) is a proven therapy to reduce morbidity and mortality for acute ischemic stroke patients (1, 2) . However, in the special group of patients presenting with an occlusion of a large intracranial vessel, IV thrombolysis on its own leads to a good clinical outcome (modified Rankin Scale [mRS] Յ2) in only 15% to 25% of these cases compared with 40% good clinical outcome in minor strokes (3, 4) . These patients are considered to be candidates for additional or primary mechanical thrombectomy. Over the last few years, numerous recanalization devices have been developed, and a large number of See page 392 prospective registries have been published (5) . Until now, we have been unaware of the clinical benefit of mechanical recanalization in the treatment of this special group of patients. Major points of criticism are that the primary endpoint of all the registries was recanalization of the target vessel, not patient outcome, although it was reported that no randomization (IV vs. mechanical treatment) took place (6, 7) .
The recently described technique of mechanical recanalization with a stent-like device showed very promising results technically and, more important, clinically (8, 9) . With this prospective study, we aimed to assess the feasibility and safety of this method.
The ReFlow (Mechanical Recanalization With Flow Restoration in Acute Ischemic Stroke) study is the first prospective trial, to our knowledge, concerning mechanical recanalization in acute ischemic stroke where the primary endpoint is the patient's clinical outcome, because previous studies mainly focused on target vessel recanalization, which does not equal good clinical outcome (10, 11) .
Materials and Methods
The ReFlow study was a prospective trial conducted at the Saarland University Hospital between September 2010 and October 2011. It was approved by the local ethics committee, and it included acute stroke patients with an intracranial large vessel occlusion treated with mechanical recanalization, 40 in number. All patients arriving at our institution within the first 6 h from stroke symptom onset were screened; those who matched the inclusion and exclusion criteria were included in the study. The inclusion and exclusion criteria are shown in Table 1 . Study design. For this prospective trial, 40 patients were enrolled between September 2010 and November 2011. The primary endpoint of the study was clinical outcome at 90 days measured with the mRS. Neurological evaluation was performed on admission and at discharge; mRS was assessed by 2 experienced stroke neurologists (S.W. and S.B.) at 90 days post-treatment. Computed tomography (CT) and CT angiography were performed on admission in order to rule out intracranial hemorrhage (ICH) and to assess vessel occlusions. Another CT control scan was obtained before discharge or if the patient's symptoms worsened. Before inclusion in the study, informed consent was obtained either from the patient or from a legal representative.
If a large vessel occlusion was found, for example, occlusion in the M1 segment of the middle cerebral artery, internal carotid artery (ICA), or in the basilar artery, treatment was started with IV tPA, provided the patients were eligible. Patients were then transferred for interventional treatment. Depending on the patient's neurological status, they were either treated under sedation or under general anesthesia with intubation and ventilation. Optimized stroke management. Emergency services are instructed to bring patients with a suspected stroke directly to the stroke treatment room in our facility, which is located next to the CT scanner. After neurological examination, the native CT scan is acquired. To reduce the time-to-treatment decision in stroke patients after arrival, point-of-care laboratory analysis is performed. This has been shown to significantly reduce the time-to-treatment decision compared with a setup where the laboratory workup is performed by a centralized laboratory (12) . If an ICH can be ruled out, CT angiography is performed. Within the 4.5-h time window, patients are treated with IV thrombolysis directly within the CT scanner after exclusion of clinical and neuroradiological contraindications. If an occlusion of a large intracranial vessel is found, the patient is transferred immediately to the angiography suite, which is located on the same floor. Depending on the patient's condition, informed consent is obtained either from the patient or from a legal representative regarding the following interventional treatment. At this point, the decision regarding treatment under sedation or intubation and ventilation is made, depending on the patient's clinical condition, such as the ability to follow commands, alertness, and so on. Interventional treatment. All procedures were performed on a biplane angiography machine (Siemens Axiom Artis, Siemens Healthcare, Munich, Germany). Mechanical recanalization was performed using a Solitaire FR revascularization device (ev3, Irvine, California). The technique has already been described (8,9) (Online Video 1). In patients with an additional atherosclerotic ICA bifurcation occlu- The ReFlow Study sion, acute stenting was performed (13) . If the patients received tPA, no heparin was given according to guidelines; the patients who were treated mechanically alone received a bolus of 3,000 IE heparin. In the case of acute carotid bifurcation stenting, 500 mg of IV aspirin were administered. The angiographic outcome was rated with the Thrombolysis In Cerebral Infarction (TICI) score, a modification of the Thrombolysis In Myocardial Infarction (TIMI) score adapted to the intracranial vasculature (Table 2 ) (14) . Post-interventional treatment. Immediately after treatment, a control CT scan was acquired to rule out procedurerelated ICH. The patients were then transferred to the stroke unit. A control CT was performed after 24 to 48 h or if the patient's symptoms worsened. Evaluation. The primary endpoint of the study was the clinical outcome after 90 days. Neurological evaluation was performed on admission and at discharge; mRS was assessed by 2 experienced stroke neurologists (S.W. and S.B.) at 90 days post-treatment. Good clinical outcome was defined as mRS Յ2.
The safety endpoints were symptomatic ICH, defined as worsening of the patient's neurological status of more than 4 on the National Institutes of Health Stroke Scale (NIHSS), and all causes of mortality at 90 days.
Secondary endpoints were recanalization of the occluded target vessel measured by the TICI (Table 2 ) score of 2b or 3, door-to-device (D2D) time (time from arrival at the hospital until the device is placed in the target lesion), door-to-recanalization time (time from arrival at the hospital until a TICI 2b or 3 state was reached), and the time from symptom onset to recanalization.
Results
Patient population. The 40 enrolled patients were selected from 65 patients with acute ischemic stroke and an intracranial large vessel occlusion arriving at our institution. The excluded patients were rejected due to unclear timeframe of symptom onset, use of warfarin with an international normalized ratio Ͼ1.5, already marked ischemia (hypodensity on CT), or rapid neurological improvement. Thirteen (32.5%) patients were treated under intubation and ventilation due to agitation; 27 patients (67.5%) were treated under IV sedation.
The enrolled patients had a mean NIHSS on admission of 16.4 with a SD of Ϯ4.1. All patients had a NIHSS score Ն10 on admission. The mean age was 70.1 Ϯ 11.8 years. The mean time frame from symptom onset to arrival was 110 min with a SD of Ϯ59 min (minimum ϭ 29 min; maximum ϭ 230 min). Eighty percent of the patients arrived within 3 h from symptom onset; the remaining 20% arrived within the first 4.5 h. Twelve patients were treated without IV tPA due to contraindications; the others received a standard 10% bolus of the maximum dose (0.9 mg/kg body weight). IV tPA was halted on accession of the target vessel; no additional IA (intra-arterial) tPA was given. All patients had a TICI score of 0 on admission. Twenty-eight patients had an M1/M2 occlusion; 10 had an occlusion of the terminal ICA; and 2 patients were treated for basilar artery occlusion. Six patients had to be treated for acute ICA bifurcation occlusion first. Table 3 provides an overview of the patients' baseline characteristics. Values are mean Ϯ SD or n (%).
Abbreviations as in Table 1 . 
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Clinical outcome. Good clinical outcome (mRS Յ2) was seen in 24 patients (60%) at 90 days. In this subgroup, 8 patients showed a mRS of 0, and 8 presented with a mRS of 1. Figure 1 provides a detailed overview of the primary endpoint.
One symptomatic hemorrhage was detected on follow-up CT; symptomatic was defined as worsening of 4 points on the NIHSS. Three hemorrhagic transformations of the infarct core were also seen without worsening of the patient's neurological status. The death rate was 12.5% (n ϭ 5) ( Table 4) . Angiographic outcome. Successful recanalization (TICI Ն2b) of the target vessel was achieved in 95% of the patients, with a mean of 1.8 runs with the device. In 12 cases (30%), a purely mechanical approach was used. In all of these patients, a TICI score of 3 was achieved. There were no visible vessel perforations with the microwire and no dissections. In 1 case, mild vasospasm in the target vessel was observed. Table 5 provides an overview of the interventional results.
The mean time from arrival of the patient until placement of the device and temporary re-establishment of flow (D2D time) was 96 min. With the optimized stroke treatment, a D2D time of Ͻ100 min was achieved in 67.5% of patients.
Patients with a D2D time of Ͻ100 min had a favorable outcome in 66% of cases, compared with 44% in patients with a D2D time of more than 100 min (Fig. 2) . Table 6 shows the various recorded times from symptom onset to recanalization, and Table 7 shows correlations between clinical outcome and various parameters.
Discussion
This prospective study demonstrates the efficacy and safety of mechanical recanalization with flow restoration in patients with a large intracranial vessel occlusion in combination with a substantial neurological deficit. The main findings are a high rate of favorable clinical outcome at 3 months (60%), a low rate of symptomatic hemorrhage (2.5%), and a low rate of mortality (12.5%). Because all the patients presented within the first 4.5 h, the results can only apply to patients presenting within this time window. Values are n (%) or mean Ϯ SD.
ICH ϭ intracranial hemorrhage; IV ϭ intravenous; mRS ϭ modified Rankin Scale; NIHSS ϭ National Institutes of Health Stroke Scale. Values are n (%) or n.
IAϭ intra-arterial; other abbreviations as in Table 1 .
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The favorable clinical outcome is higher in comparison to previous studies using flow restoration devices (45% to 50%) (9, 15) . This may reflect the fact that in this study, there was a higher rate of patients who presented within the first 3 h after symptom onset, the increased experience of the interventionalists with this technique, and the optimization of stroke treatment (12) . Furthermore, no patients beyond 6 h from stroke symptom onset were included in the study, and the treatment was started immediately after diagnosis. The clinical improvement observed in the present study is higher in comparison to the clinical outcome reported in other prospective studies in which mechanical thrombectomy devices were used. In the MERCI (Mechanical Embolus Removal in Cerebral Ischemia) trial, the functional outcome of an mRS of Յ2 was achieved in only 28% of the patients (36% in the Multi MERCI [Mechanical Embolus Removal in Cerebral Ischemia (MERCI™)] trial) (11) . The Penumbra Pivotal Stroke trial showed an outcome of mRS Յ2 in only 25% (10) . In our opinion, the improved clinical outcome with flow restoration devices is due to fast and effective clot removal, and the possibility of temporarily restoring flow between retrieval attempts, a feature that is impossible with the devices used in the MERCI, Multi MERCI, and Penumbra trials.
The rate of symptomatic ICH (2.5%) and the mortality rate (12.5%) are significantly lower compared with previous prospective studies using mechanical thrombectomy. Symptomatic intracranial hemorrhage was reported in 10% of patients with the MERCI Retriever, and in 11% with the Penumbra system. The mortality rates in the MERCI and Penumbra trials ranged from 32.5% to 44% (10, 11) . The low rate of mortality (12.5%) in our study reflects the low rate of symptomatic ICH and shows the safety of flow restoration devices compared with the MERCI device and the Penumbra system.
The high recanalization rate (95%) in our study is comparable with the recanalization rate of retrospective studies using the Solitaire FR device (9, 15) . The MERCI and Penumbra trials reported rates of successful recanalization from 43% to 78%. However, recanalization success was typically defined as a TIMI flow grade of 2 (partial) or 3 (complete) within the target vessel on angiography after the procedure, without paying attention to the distal vessel territories. Because the TICI score includes the recanalization state of distal branches, we estimate that the recanalization rates of the MERCI and Penumbra trials would have been even lower if rated with the TICI score. This confirms that flow restoration devices (stent retrievers) and especially the Solitaire FR are highly effective for thrombus removal and recanalization of the entire affected vasculature.
Another important finding of our study is that with the use of optimized stroke management, a D2D time (time from arrival at the hospital until the device is placed in the target vessel) of Ͻ100 min can be achieved in almost two-thirds of the patients. Patients with a D2D time of Ͻ100 min had a favorable outcome in 66% of patients, compared with 44% of patients with a D2D time of more than 100 min. This finding was not statically significant due to the small sample size. However, it is to be expected that Values are mean Ϯ SD or n (%).
Abbreviations as in Table 4 Correlation between D2D time and clinical outcome. Patients with a D2D time of Ͻ100 min had a favorable outcome (mRS Յ2) in 66% of cases, compared with 44% in patients with a D2D time of more than 100 min. D2D ϭ door-to-device; mRS ϭ modified Rankin Scale. by analogy with the influence of the door-to-balloon time in the outcome of patients with ST-segment elevation myocardial infarction, the D2D time might also play an important role in the outcome of these patients (16, 17) . Despite the fact that the efficacy of IV thrombolysis decreases with time, due to in-hospital delays, less than one-third of patients meet the goal of a "door-to-needle time" of 60 min or less (18) . Improvements in pre-hospital and in-hospital stroke management can translate into increased eligibility for thrombolysis and prompter treatment (19, 20) . Our optimized stroke management includes point-of-care laboratory testing instead of testing by the centralized hospital laboratory-a change that achieved important time savings in stroke management (12) . Our data suggest that physicians, hospitals, and healthcare systems should work to reduce the "door-to-device" time, as has been done for "door-to-balloon" time in ST-segment elevation myocardial infarction patients by the American Heart Association (21-23). Moreover, we suggest that in randomized trials for comparison of mechanical thrombectomy to IV thrombolysis, a limit should be defined for D2D time. Study limitations. All patients presented within the first 4.5 h after symptom onset, so the results can only apply to patients presenting within this time window, which makes the study slightly less comparable to previous studies that included patients up to 8 h from symptom onset. Another limitation is the lack of a control group (patients treated with IV thrombolysis on its own) with which to compare the results.
Conclusions
The ReFlow study shows that mechanical recanalization with flow restoration is highly effective in patients presenting within 4.5 h after symptom onset. To confirm these results, there is no doubt that a randomized trial is needed to compare mechanical recanalization plus IV thrombolysis with IV thrombolysis on its own. Our study demonstrates that in such a trial, a flow restoration device should be used for mechanical thrombectomy, and optimized in-hospital stroke management in which a limit of D2D time should be defined.
